Welcome to our dedicated page for Estrella Immunopharma SEC filings (Ticker: ESLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech filings are notoriously dense, and Estrella Immunopharma Inc’s SEC documents are no exception. The company’s 10-K drills deep into ARTEMIS T-cell trial protocols, while each 10-Q updates investors on cash runway and R&D burn. If you have ever hunted through an 8-K for a single sentence about a dose-escalation milestone—or tried to spot dilution risk hidden in a shelf registration—you know the challenge. That’s why users search phrases like “Estrella Immunopharma SEC filings explained simply” and “Estrella Immunopharma 8-K material events explained.”
Stock Titan solves the problem. Our AI parses every new filing the moment it hits EDGAR, delivering plain-English summaries and red-flag alerts. Need the “Estrella Immunopharma quarterly earnings report 10-Q filing” breakdown? It’s there, with side-by-side metrics and historical comps. Want “Estrella Immunopharma insider trading Form 4 transactions” in real time? Instant alerts show each executive stock move. The platform covers every form investors care about, including:
- Annual report 10-K—trial timelines, liquidity, risk factors
- 10-Q—quarterly R&D spend and enrollment updates
- 8-K—material press releases decoded
- Form 4—executive stock transactions, updated live
- Proxy statement—“Estrella Immunopharma proxy statement executive compensation” distilled into key numbers
Use the insights to compare phases, monitor dilution signals, or track Form 4 insider buys. From “understanding Estrella Immunopharma SEC documents with AI” to detailed “Estrella Immunopharma earnings report filing analysis,” Stock Titan transforms complexity into clarity. Make better calls on trial progress, funding needs, and management confidence—without wading through hundreds of pages.
Estrella Immunopharma (ESLA) reported that it completed the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103. The company announced the milestone via a press release dated November 3, 2025, which is furnished as Exhibit 99.1 to this report.
Estrella Immunopharma director Jia Dengyao filed an initial Form 3 reporting no securities beneficially owned in the company. The form lists Dengyao's relationship to the issuer as a director and provides a business address. Table entries indicate there are no non-derivative or derivative holdings to report, and the reporting person signed the filing certifying the accuracy of the statement.
FAQ
What is the current stock price of Estrella Immunopharma (ESLA)?
What is the market cap of Estrella Immunopharma (ESLA)?
